Global Intranasal Drug And Vaccine Delivery Market by Product (Liquid Delivery Device, Powder Delivery Device) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

Summary of the Report

Global intranasal drug delivery and vaccine market was worth USD 49.78 Billion in 2019. It is expected to grow at a 6.5% compound annual growth rate (CAGR), between 2020 and 2027. The market growth is fueled by the increasing prevalence of neurological and respiratory diseases, and an increase in intranasal product launch.

Market players are developing new nasal drug delivery technologies to administer COVID-19 vaccines. This market is expected grow rapidly over the forecast period. Bharat Biotech began clinical trials for its COVID-19 nasal drops vaccine on 7 April 2020. For human trials in the U.S., the company has partnered with FluGen ( vaccinator developer FluGen)

The market is driven by a growing preference for nasal products. They are non-invasive and well tolerated, which increases patient compliance. Technology has advanced in nasal drug delivery systems. There is increasing scientific evidence that nasal delivery of drugs can be used to treat central nervous system disorders. Even higher concentrations can be delivered via the nasal route. This allows for better needleless treatment of patients with CNS disorders. The global market growth may be impeded by side effects and moderate complications associated with nasal products.

The demand for non-invasive drug delivery methods for chronic diseases such as allergies, rhinitis and migraine is increasing. The International Study of Asthma and Allergies in Childhood published in World Allergy Organisation Journal 2018 shows that allergic rhinitis prevalence is anywhere from 0.8% to 14.9% in 6-7 year olds and 1.4% to 39.7% in 13-14 year olds.

In a study published by the U.S. National Library of Medicine National Institutes of Health, it was found that allergic rhinitis prevalence in Asia, America and Europe ranged from 15% to 25%. The number of Americans suffering from sinusitis in 2016 was approximately 26.9 millions, which is 11.0% of all adults in the United States. These diseases can be treated with nasal products. According to a study published by the U.S. National Library of Medicine National Institutes of Health, migraine prevalence rates range from 2.6% to 21.7%. The nasal route is the most common method of treating migraine. Market growth is expected to be fueled by the rising incidence of chronic illnesses.

Product Insights

The market for intranasal drug delivery and vaccine delivery can be divided into powder delivery device and liquid delivery device. The largest market share, 42.8%, was held by liquid delivery devices in 2019, which are available in a variety of formulations such as suspensions, emulsions and aqueous solutions. Segment growth is expected to be accelerated by frequent innovations and the introduction of new devices for different indications. Aptar Pharma, a provider of drug delivery systems, was granted FDA approval in March 219 for its Bidose nasal spray device. The breakthrough therapy approval was given to the liquid device for the treatment of depression. Pharmapack awarded Safe'n'Spray the Best Innovation Award in February 2020. It is an electronic nasal spray device that Nemera's developed. It features overdosing prevention and fingerprint identification, which allow for child resistance and security.

As powder delivery devices are relatively stable, the market segment for powder delivery devices is expected to grow. High dose concentrations of peptides and hormones can be administered easily in powder nasal sprays. To capture a large market share, market players are focusing on patient-friendly drug delivery strategies. AptarGroup, Inc. was granted approval by the U.S. Food and Drug Administration for Unidose Powder System in July 2019. This needle-free, intranasal treatment is indicated for severe hypoglycemia patients with diabetes.

Dosage Insights

The market for intramuscular drug and vaccine delivery can be divided into two types based on the dosage: multi-dose and unit-dose. With a 64.5% share in 2019, multi-dose spray pumps led the market. They are a convenient, cost-effective and safe choice for patients with chronic diseases like allergic rhinitis.

Over the forecast period, the single-dose or unit-dose segment will experience the greatest growth. Medical professionals often recommend a single dose of vaccine, so the majority are unit-dose vaccine formulations. Segment growth will also be boosted by increasing approvals for treatment of different disorders. Insys Therapeutics, Inc. developed a unit-dose nasal spray for opioid overdose emergency treatment. It was approved by the FDA in July 2019. The Centers for Disease Control and Prevention reported that 47,600 deaths from opioid overdoses were recorded in the United States in 2017.

Distribution Channel Insights

The market for intramuscular drug and vaccine delivery can be divided into three segments based on distribution channels: online pharmacies (retail pharmacies), hospital pharmacies (retail pharmacies) and online pharmacies (online pharmacies). In 2019, the largest share was held by the retail pharmacies segment at 45.3%. This is due to increased patient awareness, self-administration and a greater focus on positive medical outcomes. Device developers have been working with many pharmacie chains to make point-of-care medication available without the need for a prescription. Rx Edge Media Network (CVS Health) and Emergent BioSolutions launched a program in November 2019 to allow Narcan anti-opioid overdose nasal spray over the counter.

Due to the numerous discount offers offered by developers through bulk purchases of essential drugs delivery devices, the online pharmacy segment is expected to grow the fastest over the forecast period. Cost-effectiveness for patients and payers is an important factor in chronic disease management. The medications must be administered frequently, which provides an economic option for patients in developing and underdeveloped countries.

Application Insights

Based on the application, there are three segments in the market for intramuscular drug and vaccine delivery: respiratory disorders, neurological disorders and pain management. In 2019, the largest share was held by the respiratory disorders segment, which accounted for 41.2%. This can be mainly attributed the widespread use of intranasal devices to treat a wide range of respiratory disorders such as asthma, allergic rhinitis, and nasal congestion.

The Centers for Disease Control and Prevention estimates that 26.5 million Americans have asthma. In 2015, there were approximately 1.7 million asthma-related emergency room visits. According to a study published in The Journal of Allergy and Clinical Immunology in 2016, allergic rhinitis was reported to affect 10-40% of the global population. Allergy rhinitis can be treated with drops, sprays, nebulizers, irrigations, and nasal sprays. In March 2020, the American College of Allergy, Asthma & Immunology (ACAAI), published a guideline document that allowed patients suffering from allergies and asthma to continue using intranasal corticosteroids in the COVID-19 pandemic.

Regional Insights

North America was the dominant market, with 44.2% of the market in 2019, due to increased demand for nasal drug delivery systems and FDA approvals. Aptar Pharma's Bidose nasal spray device for depression was approved by the U.S. FDA in March 2019. The market is expected to grow due to an increase in chronic diseases such as sinusitis or rhinitis. The Centers for Disease Control and Prevention estimates that approximately 11% of Americans were affected by sinusitis in 2016. This is a total of 26.9 millions people. According to a World Federation of Allergy, Asthma & Clinical Immunology Societies article, rhinitis affected between 10% and 30% of Americans in 2015. Nearly 40% of American children also suffered from it in 2015.

Asia Pacific will experience the fastest growth during the forecast period. This can be attributed to increased product development protocols, economic growth and an increase of local market players that are able to develop new drug delivery systems. Bharat Biotech, an Indian vaccine developer, joined FluGen and University of Wisconsin-Madison to develop an intranasal COVID-19 vaccination.

Market Share Insights & Key Companies

To gain a substantial share of the global market, market players have adopted a variety of strategies to increase their market share, including significant investments in research and development, product innovations, and geographic expansion in developing countries. Many developers are focusing on the development of cost-effective generic nasal drug delivery systems, which will help boost market growth and increase access to emergency treatment. Teva Pharmaceuticals, a manufacturer of generic naloxone nasal sprays, approved the first generic naloxone nasal spray in April 2019. This nasal spray was developed for opioid overdose. The following are some of the most prominent players in the global market for intranasal vaccine and drug delivery:

• GlaxoSmithKline Plc

• Teva Pharmaceuticals

• Aptar Pharma

• UCB, Inc.

• Teleflex Corporation

• 3M

• Bespak

• OptiNose, Inc.

• Intersect ENT

Up Market Research published a new report titled “Intranasal Drug And Vaccine Delivery Market research report which is segmented by Product (Liquid Delivery Device, Powder Delivery Device), By Players/Companies Bespak, Intersect ENT, OptiNose Inc, Aptar Pharma, GlaxoSmithKline Plc, UCB Inc, Teva Pharmaceuticals, 3M, Teleflex Corporation”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

Report Scope

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.

Global Intranasal Drug And Vaccine Delivery Market Report Segments:

The market is segmented by Product (Liquid Delivery Device, Powder Delivery Device).

Intranasal Drug And Vaccine Delivery Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

Key Benefits for Industry Participants & Stakeholders:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Intranasal Drug And Vaccine Delivery Market

Overview of the regional outlook of the Intranasal Drug And Vaccine Delivery Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.

Highlights of The Intranasal Drug And Vaccine Delivery Market Report:

1. The market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends of Intranasal Drug And Vaccine Delivery Market.
3. Historical data and forecast.
4. Estimations for the forecast period 2028.
5. Developments and trends in the market.

                1. Liquid Delivery Device

                2. Powder Delivery Device

7. Market scenario by region, sub-region, and country.
8. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
9. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
10. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Intranasal Drug And Vaccine Delivery Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

How you may use our products:

• Correctly Positioning New Products
• Market Entry Strategies
• Business Expansion Strategies
• Consumer Insights
• Understanding Competition Scenario
• Product & Brand Management
• Channel & Customer Management
• Identifying Appropriate Advertising Appeals

Reasons to Purchase the Intranasal Drug And Vaccine Delivery Market Report:

• The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
• Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
• Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
• The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
• Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.